GlassScriptPhysician profile
Mikhail R Malek
NPI 1467455212
$6,948.14
in general payments reported to CMS, 2019-2025
24 companies · $179 in 2025
The $179 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,540 · 2020: $1,908 · 2021: $561 · 2022: $560 · 2023: $854 · 2024: $346 · 2025: $179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,379.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,378.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $3,853.41 | 2019-2020 | |
| Abbott Laboratories | $577.21 | 2019-2024 | Mitraclip, Pressurewire |
| Biotronik INC. | $539.88 | 2020-2025 | Amvia Edge, Pantera Leo, Orsiro Mission |
| Boston Scientific Corporation | $507.72 | 2019-2024 | Avvigo Guidance System, Rotapro, Synergy |
| Abiomed | $258.20 | 2019-2023 | Impella |
| Medtronic, INC. | $223.18 | 2022-2025 | Onyx Frontier |
| Shockwave Medical, INC | $166.88 | 2021 | |
| Edwards Lifesciences Corporation | $157.51 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $123.12 | 2021-2023 | Lifevest |
| Actelion Pharmaceuticals US, INC. | $70.04 | 2021-2022 | |
| Bard Peripheral Vascular, INC. | $61.05 | 2022 | |
| Novartis Pharmaceuticals Corporation | $57.26 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $54.03 | 2019-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $48.58 | 2019-2023 | Camzyos |
| Pfizer INC. | $46.41 | 2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiva Medical, INC. | $42.33 | 2023 | Cardiva Vascade 6/7f Vcs |
| Philips North America LLC | $41.58 | 2020-2024 | (Ck4) Mcot |
| Merck Sharp & Dohme LLC | $23.39 | 2022 | |
| Irhythm Technologies, INC. | $19.91 | 2022 | |
| Cvrx, INC. | $17.43 | 2024 | Barostim Neo System |
| Astrazeneca Pharmaceuticals LP | $17.17 | 2023 | Andexxa |
| Bardy Diagnostics, INC. | $15.00 | 2021 | |
| Amgen INC. | $14.87 | 2025 | Repatha |
| Chiesi USA, INC. | $11.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mikhail Malek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.